Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.
Donna Ellen Reece
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Otsuka
Research Funding - Bristol-Myers Squibb; Celgene; Janssen; Merck; Millennium; Novartis; Otsuka
Ute Hegenbart
Honoraria - Janssen
Vaishali Sanchorawala
Research Funding - Celgene; Millennium; Onyx
Giampaolo Merlini
Consultant or Advisory Role - Elan; Pfizer
Giovanni Palladini
No relevant relationships to disclose
Joan Blade
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Jean-Paul Fermand
No relevant relationships to disclose
Hani Hassoun
Research Funding - Millennium
Leonard Heffner
Honoraria - Millennium
Research Funding - Millennium
Other Remuneration - Millennium
Lixia Pei
Employment or Leadership Position - Janssen Research & Development
Christopher Enny
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Dixie Esseltine
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Helgi Van De Velde
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Andrew Cakana
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Raymond Comenzo
Consultant or Advisory Role - Millennium
Research Funding - Millennium